Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.

被引：1
|
作者：
Xue, Cong
Yao, Herui
Lin, Ying
An, Xin
Chen, Meiting
Dong, Yugang
Li, Su
Shi, Yanxia
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[2] State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
    Xue, Cong
    Li, Haifeng
    Yao, Herui
    Lin, Ying
    An, Xin
    Chen, Meiting
    Huang, Riqing
    Li, Lu
    Hu, Anqi
    Ni, Mengqian
    Zhang, Lulu
    Yang, Wei
    Xu, Zhonghui
    Li, Su
    Shi, Yanxia
    [J]. NPJ BREAST CANCER, 2022, 8 (01)
  • [2] Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
    Cong Xue
    Haifeng Li
    Herui Yao
    Ying Lin
    Xin An
    Meiting Chen
    Riqing Huang
    Lu Li
    Anqi Hu
    Mengqian Ni
    Lulu Zhang
    Wei Yang
    Zhonghui Xu
    Su Li
    Yanxia Shi
    [J]. npj Breast Cancer, 8
  • [3] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [4] A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
    Zhao, Meng
    Pan, Xueliang
    Layman, Rachel
    Lustberg, Maryam B.
    Mrozek, Ewa
    Macrae, Erin R.
    Wesolowski, Robert
    Carothers, Sarah
    Puhalla, Shannon
    Shapiro, Charles L.
    Ramaswamy, Bhuvaneswari
    [J]. INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1285 - 1294
  • [5] A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
    Meng Zhao
    Xueliang Pan
    Rachel Layman
    Maryam B. Lustberg
    Ewa Mrozek
    Erin R. Macrae
    Robert Wesolowski
    Sarah Carothers
    Shannon Puhalla
    Charles L. Shapiro
    Bhuvaneswari Ramaswamy
    [J]. Investigational New Drugs, 2014, 32 : 1285 - 1294
  • [6] Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer
    Gil, M.
    Martin, M.
    Antolin, S.
    Trigo, J. M.
    Guerrero, A.
    Vidal, L.
    Urruticoechea, A.
    Pandiella, A.
    Hernando, A.
    Ocana, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S180
  • [7] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [8] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [9] Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
    Ring, Alistair
    Wheatley, Duncan
    Hatcher, Helen
    Laing, Robert
    Plummer, Ruth
    Uttenreuther-Fischer, Martina
    Temple, Graham
    Pelling, Katy
    Schnell, David
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2737 - 2744
  • [10] Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
    Mundi, P. S.
    Lee, S.
    Chi, D.
    Bhardwaj, A.
    Makower, D.
    Cigler, T.
    Crew, K. D.
    Hershman, D. L.
    Califano, A.
    Silva, J.
    Kalinsky, K. M.
    [J]. CANCER RESEARCH, 2017, 77
12345